With potentially "single dosing curative paradigm" promised by CAR-T therapies there is a paradigm shift in the treatment and management of hematologic malignancies, and the field is rapidly evolving. US FDA approved CAR-T therapies now extend beyond CD-19 targeting CAR Ts to also include the most recently approved BCMA CAR-T for relapsed refractory multiple myeloma. Advancements in the field are also being made towards reducing the long and difficult wait for critically ill patients with "off-the shelf" allogenic CAR-T therapies now in various stages of clinical development. From initial focus to only hematologic malignancies, indications are now broadening to solid tumors with a focus on TCR-T therapies for solid tumors in clinical development. There are unique clinical pharmacology and biopharmaceutic aspects of development of CAR-T therapies that offer challenges yet great opportunities for optimization of the clinical development for this important class of therapies. This oral presentation will highlight those.